Literature DB >> 33113500

Genistein nanoformulation promotes selective apoptosis in oral squamous cell carcinoma through repression of 3PK-EZH2 signalling pathway.

Atul Dev1, Mohammed Nadim Sardoiwala1, Avinash Chandra Kushwaha1, Surajit Karmakar2, Subhasree Roy Choudhury3.   

Abstract

BACKGROUND: Overexpression of polycomb protein contributes to epigenetic repression in oral squamous cell carcinoma (OSCC) ensuing in poor prognosis and aggressive phenotype. Several plant-based compounds could help prevent epigenome alteration and cancer progression, but their low bioavailability limits their therapeutic activity. HYPOTHESIS: In this study, we have synthesized genistein nanoformulation (GLNPs) and evaluated its epigenetic regulation mechanism for selective apoptosis induction in OSCC.
METHODS: Lactalbumin was used to prepare nanoformulation of Genistein. The mechanism of epigenetic regulation and selective apoptosis by Genistein loaded nanoparticles was studied in OSCC cell line JHU011 and fibroblast cell line L929 using immunofluorescence, Western blotting and ChIP-qPCR assay.
RESULTS: We have found that GLNPs treatment selectively induced apoptosis in OSCC compared to the normal fibroblast cells. This selective effect in OSCC is achieved through enhanced reactive oxygen species (ROS) generation followed by Bax mitochondrial translocation and caspase 3 activation. Further, GLNPs induced withdrawal of epigenetic transcription repression through concurrent downregulation of the polycomb group proteins (PcG) Bmi 1 and EZH2 along with their successive targets, UbH2AK119 and H3K27me3, which have immense therapeutic implications in the treatment of OSCC. Last, we have established that GLNPs regulate EZH2expression through proteasomal mediated degradation and 3PK inhibition; 3PK protein was found physically linked with EZH2 protein and its promoter region (-1107 to -1002). This event indicates that 3PK might play some crucial role in EZH2 expression and epigenetic control of OSCC. Moreover, the formulation showed improved biodistribution, aqueous dispersibility and enhanced biocompatibility In-vivo.
CONCLUSIONS: These results provide evidence that GLNPs may withdraw epigenetic transcriptional repression and selectively induce apoptosis in human oral squamous cell carcinoma.
Copyright © 2020. Published by Elsevier GmbH.

Entities:  

Keywords:  3PK-EZH2 axis; Epigenetic regulation; Genistein; Oral squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 33113500     DOI: 10.1016/j.phymed.2020.153386

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  4 in total

1.  Genistein anticancer efficacy during induced oral squamous cell carcinoma: an experimental study.

Authors:  Ahmed M Hussein; Abdelraheim H Attaai; Asmaa M Zahran
Journal:  J Egypt Natl Canc Inst       Date:  2022-09-05

Review 2.  Genistein as a regulator of signaling pathways and microRNAs in different types of cancers.

Authors:  Zeeshan Javed; Khushbukhat Khan; Jesús Herrera-Bravo; Sajid Naeem; Muhammad Javed Iqbal; Haleema Sadia; Qamar Raza Qadri; Shahid Raza; Asma Irshad; Ali Akbar; Željko Reiner; Ahmed Al-Harrasi; Ahmed Al-Rawahi; Dinara Satmbekova; Monica Butnariu; Iulia Cristina Bagiu; Radu Vasile Bagiu; Javad Sharifi-Rad
Journal:  Cancer Cell Int       Date:  2021-07-21       Impact factor: 6.429

Review 3.  Targeting Cancer Stem Cells by Dietary Agents: An Important Therapeutic Strategy against Human Malignancies.

Authors:  Mahshid Deldar Abad Paskeh; Shafagh Asadi; Amirhossein Zabolian; Hossein Saleki; Mohammad Amin Khoshbakht; Sina Sabet; Mohamad Javad Naghdi; Mehrdad Hashemi; Kiavash Hushmandi; Milad Ashrafizadeh; Sepideh Mirzaei; Ali Zarrabi; Gautam Sethi
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

4.  Chemopreventive efficacy of salvianolic acid B phospholipid complex loaded nanoparticles against experimental oral carcinogenesis: implication of sustained drug release.

Authors:  Wei Liu; Zengtong Zhou; Laikuan Zhu; Hongquan Li; Lan Wu
Journal:  Ann Transl Med       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.